Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of BR005-036C for Acute Treatment of Migraine
NCT07835152Phase 3Not yet recruiting
- Sponsor
- Brise Pharmaceuticals
- Start
- Sep 2026
- Primary completion
- Mar 2029
- Countries
- 1
01
Overview
A Phase 3 trial of BR005-036C in migraine, sponsored by Brise Pharmaceuticals. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
BR005-036C
03
Conditions
migraine
Beyond the preview
Go deeper on NCT07835152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07835152.